Luc Van Hijfte

Publications (2)6 Total impact

• Article: Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

  Patrick Angibaud, Kristof Van Emelen, Laurence Decrane, Sven van Brandt, Peter Ten Holte, Isabelle Pilatte, Bruno Roux, Virginie Poncelet, David Speybrouck, Laurence Queguiner, [......], Ron Gilissen, Claire Mackie, Marc Du Jardin, Jozef Peeters, Marc Noppe, Luc Van Hijfte, Eddy Freyne, Martin Page, Michel Janicot, Janine Arts
  [show abstract] [hide abstract]
  ABSTRACT: Pursuing our efforts in designing 5-pyrimidylhydroxamic acid anti-cancer agents, we have identified a new series of potent histone deacetylase (HDAC) inhibitors. These compounds exhibit enzymatic HDAC inhibiting properties with IC(50) values in the nanomolar range and inhibit tumor cell proliferation at similar levels. Good solubility, moderate bioavailability, and promising in vivo activity in xenograft model made this series of compounds interesting starting points to design new potent HDAC inhibitors.
  Bioorganic & medicinal chemistry letters 10/2009; 20(1):294-8. · 2.65 Impact Factor
• Article: Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.

  Patrick Angibaud, Janine Arts, Kristof Van Emelen, Virginie Poncelet, Isabelle Pilatte, Bruno Roux, Sven Van Brandt, Marc Verdonck, Hans De Winter, Peter Ten Holte, [......], Boudewijn Janssens, Jacky Van Dun, An Aerts, Jacky Van Gompel, Sandrine Gaurrand, Laurence Queguiner, Jean-Michel Argoullon, Luc Van Hijfte, Eddy Freyne, Michel Janicot
  [show abstract] [hide abstract]
  ABSTRACT: A series of pyrimidyl-5-hydroxamic acids was prepared for evaluation as inhibitors of histone deacetylase (HDAC). Amino-2-pyrimidinyl can be used as a linker to provide HDAC inhibitors of good enzymatic potency.
  European Journal of Medicinal Chemistry 07/2005; 40(6):597-606. · 3.35 Impact Factor